Antivascular therapy of cancer metastasis

Journal of Surgical Oncology

Volumn 94, Issue 3, 2006, Pages 178-180

  Fidler, Isaiah J ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL SURFACE RECEPTOR; DOCETAXEL; IMATINIB; PACLITAXEL; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; BONE METASTASIS; CLINICAL ARTICLE; CLINICAL TRIAL; ENDOTHELIUM CELL; HUMAN; LYMPH NODE METASTASIS; METASTASIS; MOUSE; NONHUMAN; NOTE; PATHOGENESIS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; TUMOR CELL;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; DISEASE PROGRESSION; GROWTH SUBSTANCES; HUMANS; MALE; MICE; MICE, NUDE; NEOPLASM METASTASIS; NEOPLASMS; PACLITAXEL; PIPERAZINES; PLATELET-DERIVED GROWTH FACTOR; PROSTATIC NEOPLASMS; PYRIMIDINES; RECEPTORS, GROWTH FACTOR; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR;

EID: 33747880994     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.20380     Document Type: Note

References (13)

1. Fidler IJ: Critical factors in the biology of human cancer metastasis: Twenty-eighth G.H.A. Clowes Memorial Award Lecture. Cancer Res 1990;50:6130-6138.
2. Fidler IJ, Kripke ML: Metastasis results from preexisting variant cells within a malignant tumor. Science 1977;197:893-895.
3. Fidler IJ: The pathogenesis of cancer metastasis: The 'seed and soil' hypothesis revisited (Timeline). Nat Rev Cancer 2003;3:453-458.
4. Paget S: The distribution of secondary growths in cancer of the breast. Lancet 1889;1:591-593.
5. Fidler IJ, Yano S, Zhang R-D, et al.: The seed and soil hypothesis: Vascularization and brain metastases (Personal View). Lancet Oncol 2002;3:53-57.
6. Folkman J: Angiogenesis in cancer, vascular, rheumatoid, and other diseases. Nat Med 1995;1:27-31.
7. Fidler IJ, Langley RR, Kerbel RS, et al.: Biology of cancer: Angiogenesis. In: DeVita VT, Jr., Hellman S, Rosenberg SA, editors. Cancer: Principles and practice of oncology, 7th edn. Philadelphia, PA: Lippincott & Wilkins, 2005. pp 129-137.
8. Uehara H, Kim SJ, Karashima T, et al.: Effects of blocking platelet-derived growth factor-receptor signaling in a mouse model of prostate cancer bone metastasis. J Natl Cancer Inst 2003;95:458-470.
9. Eberhard A, Kahlert S, Goede V, et al.: Heterogeneity of angiogenesis and blood vessel maturation in human tumors: Implications for antiangiogenic tumor therapies. Cancer Res 2000;60:1388-1393.
10. Klement G, Baruchel S, Rak J, et al.: Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 2000;105:R15-R24.
11. Druker BJ, Tamura S, Buchdunger E, et al.: Effects of a selective inhibitor of the AbI tyrosine kinase on the growth of Bcr-Abl-positive cells. Nat Med 1996;2:561-565.
12. Kim SJ, Uehara H, Yazici S, et al.: Simultaneous blockade of platelet-derived growth factor-receptor and epidermal growth factor receptor signaling and systemic administration of Paclitaxel as therapy for human prostate cancer metastasis in bone of nude mice. Cancer Res 2004;64:4201-4208.
13. Mathew P, Fidler IJ, Logothetis CJ: Combination Docetaxel and platelet-derived growth factor receptor inhibition with imatinib mesylate in prostate cancer. Semin Oncol 2004;31:24-29.